TRIAL DETAIL

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Drug:
Trial Name:
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
NCT#:
Conditions:
Any type of Cancer
Status:
Active, not recruiting
Phase:
2
Start Date 03/01/2014
Age of Trial (yrs) 8.3
Treatment Phase:
All
Drug Category:
BRAF Inhibitor + MEK Inhibitor
Strategy:
Block BRAF
Trial Type:
Specifically GIST plus other cancers
Other Protocol IDs:
117019
Sponsor:
GlaxoSmithKline
Patient Contact:
US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
Inquiries should be directed first to the GSK contacts.

There are 47 sites open or pending. 35 in Europe, 8 in the US, 3 in the Republic of Korea and 1 in Canada. Current site information is available in the trial listing at the clinicaltrials.gov site. Click on the NCT # and expand the Contacts and Locations section to se the most recent listings and status.

Subjects will need to have a fresh or frozen tumor tissue sample provided to confirm the BRAF V600E mutation status.

Only subjects with histologically confirmed advanced disease and no available standard treatment options will be eligible for enrollment.

Inclusion criteria: BRAF V600E mutation-positive tumor
French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country